H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today and set a price target of ...
Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine ...
Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “”, Nasdaq: OLMA), a clinical-stage ...
Olema Pharmaceuticals shares rose 5.3% in premarket trading Monday after its investigational new drug application for OP-3136 was approved by the Food and Drug Administration. Shares were trading ...
Olema presented Phase 1b/2 trial data for palazestrant combined with Novartis's Kisqali in ER-positive, HER2-negative breast ...
"We are very pleased to have received notification from the FDA that OP-3136 may proceed into the clinic,” said David C. Myles, Ph.D., Chief Discovery and Non-Clinical Development Officer of Olema ...
Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.
Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 mutations, and 23% maturity among all patients, ...
It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...
Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...
Wednesday, December 11 Santa Claus at Buttermilk Baby Buttermilk Baby, 600 North Shepherd, invites folks to a special visit ...